Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
3841 studies found for:    5-HT
Show Display Options
Rank Status Study
1 Completed
Has Results
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Fosaprepitant;   Drug: Dexamethasone;   Drug: 5HT3
2 Recruiting Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation
Condition: Healthy Volunteers
Intervention: Drug: Sumatriptan
3 Completed Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Condition: Migraine
Interventions: Drug: Rapimelt;   Drug: [11C]AZ10419369
4 Recruiting Investigation of Serotonin Receptor Binding in the Migraine Brain Using Positron Emission Tomography
Condition: Migraine Without Aura
Intervention: Other: PET scan with two different 5-HT receptor ligands
5 Completed Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a
Condition: Parkinson Disease
Intervention: Drug: [18F]MPPF
6 Completed Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors
Condition: Healthy
Interventions: Drug: Citalopram and Pindolol;   Other: Placebo;   Dietary Supplement: Acute tryptophan depletion
7 Unknown  Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension
Conditions: Hypotension;   Shivering;   Nausea and Vomiting;   Vasopressor
Interventions: Drug: ramosetron;   Drug: ondansetron;   Drug: placebo
8 Recruiting 5-HT3 Antagonists (Antiemetics) and Cardiac Safety
Condition: Adverse Reaction to Other Drugs and Medicines
Intervention: Drug: Ondansetron
9 Not yet recruiting Effects of TBS on 5-HT1A Receptor Binding
Condition: Treatment Resistant Depression
Interventions: Device: theta-burst stimulation using a MagPro X1000;   Device: sham stimulation using a MagPro X1000
10 Withdrawn Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder
Conditions: Major Depression;   Unipolar Depression;   Depression;   Anxiety Disorder
Intervention: Other: Antidepressant (SSRI)
11 Active, not recruiting 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Conditions: Opioid Withdrawal;   Physical Dependence
Intervention: Drug: Ondansetron
12 Recruiting Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing
Condition: Healthy
Interventions: Drug: LSD;   Drug: MDMA;   Drug: Amphetamine;   Drug: Placebo
13 Completed An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
Condition: Depressive Disorder
Intervention: Drug: MDL100.907
14 Completed The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers
Condition: Healthy
Interventions: Drug: Placebo;   Drug: LSD;   Drug: Ketanserin
15 Completed PET Imaging of Brain 5-HT(1A) Receptors Using [(11)C](-)-RWAY
Condition: Healthy Volunteers
Intervention: Drug: [11C] (-)-RWAY
16 Completed Association of 5-HT3 Receptor Gene Polymorphism With the Efficiency of Ondansetron for Postoperative Nausea and Vomiting
Condition: Post Operative Nausea and Vomiting
Intervention: Dietary Supplement: administration of ondanstron and screening of genomic DNA
17 Completed The Plasma Serotonin and Aortic Stenosis: a Pilot Study.
Condition: Aortic Stenosis
Intervention: Procedure: biomarkers
18 Unknown  Hiperemezis and Serotonin Elevated Serum Serotonin Levels in Hyperemesis
Conditions: Nausea;   Vomiting;   Markedly Reduced Food Intake;   Severe Dehydration
Intervention:
19 Completed Tryptophan, Serotonin and Kynurenine in Septic Shock
Condition: Shock, Septic
Intervention:
20 Completed
Has Results
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
Condition: Gastroesophageal Reflux Disease
Interventions: Drug: SSP-002358 (0.1 mg) + PPI;   Drug: SSP-002358 (0.5 mg) + PPI;   Drug: SSP-002358 (2.0 mg) + PPI;   Drug: Placebo + PPI

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.